Managed Pain Care › Women & Pain

Women's pain is different.
That's the record, not an opinion.

For decades, medicine studied one average body — usually a man's — and dosed everyone else off it. Here's what that cost, and why MPC is built around your body, not the average.

The gap nobody fixed for years

"Drugs for women, tested on men"

It sounds like an exaggeration. It isn't. Until the NIH Revitalization Act of 1993, women weren't even required to be included in U.S. federally funded clinical research. Before that — thanks in part to a 1977 FDA guidance that kept women of childbearing potential out of early trials — a huge share of the medicines women were handed had been designed and tested largely on men's bodies.

So "the standard dose" and "the standard schedule" for those drugs were calibrated on a body that often metabolizes them differently. The gap didn't close in 1993 either — it just finally started being measured.

The example that finally got noticed

Ambien: same pill, half the dose

In January 2013 — after the drug had been on the market for roughly two decades — the FDA cut the recommended dose of the sleep medication zolpidem (Ambien) for women: immediate-release from 10 mg down to 5 mg, and extended-release (Ambien CR) down to 6.25 mg. The reason on the record: women clear the drug more slowly, so the "standard" dose left them with higher blood levels the next morning — impaired enough to be a driving risk.

20 yrs
of women taking the same dose as men before the number was changed. Ambien isn't the exception — it's the clearest example of the rule.
Why this is the heart of MPC

You are not the average

Metabolism. Sex. Hormones. The menstrual cycle. These are exactly the variables that "the average patient" erases — and they're the difference between a treatment that fits and one that doesn't. It's the same reason two people can take the identical medication and have completely different results.

MPC was built on a single stubborn idea: you deserve your own data, not the average's. Not a study's mean. Not a chart drawn from someone else's body. Yours.

The dose was never wrong for everyone. It was wrong for the people no one measured.
What MPC does about it

Track what standard research averages away

MPC lines up your pain against the things generic tools ignore — your medications and their timing, the environment, and your menstrual cycle New, logged right alongside everything else so cyclical patterns can surface in your data. Hormonal shifts are one of the best-documented pain triggers there is — and one of the least tracked.

Same as everywhere else in MPC: we show you your patterns — we don't diagnose or predict. Here's your data. You decide what it means.

Your cycle data never leaves your phone.

Cycle information is some of the most sensitive data there is. In MPC it stays on your device — never uploaded, never sold, deletable anytime. You share it only if you choose to, with whom you choose.

Sources

This page stands on the record

[1] U.S. Food & Drug Administration. FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses (zolpidem) (2013). fda.gov
[2] Liu, K. A., & Mager, N. A. D. (2016). Women's involvement in clinical trials: historical perspective and future implications. Pharmacy Practice. / Inclusion of Women in Clinical Trials: A Historical Overview. JOGNN
[3] NIH Revitalization Act of 1993 — mandated inclusion of women and minorities in NIH-funded clinical research. Overview
[4] "20 Years Later, Drugs Do Act Differently in Women." Applied Clinical Trials. Link